These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34064775)

  • 1. Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.
    Klinger D; Hill BL; Barda N; Halperin E; Gofrit ON; Greenblatt CL; Rappoport N; Linial M; Bercovier H
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34064775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    Wang E; Hagberg O; Malmström PU
    PLoS One; 2023; 18(12):e0292174. PubMed ID: 38096211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients.
    Gofrit ON; Klein BY; Cohen IR; Ben-Hur T; Greenblatt CL; Bercovier H
    PLoS One; 2019; 14(11):e0224433. PubMed ID: 31697701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Bacillus Calmette-Guérin Treatment Is Inversely Associated With the Risk of Developing Alzheimer Disease or Other Dementia Among Patients With Non-muscle-invasive Bladder Cancer.
    Kim JI; Zhu D; Barry E; Kovac E; Aboumohamed A; Agalliu I; Sankin A
    Clin Genitourin Cancer; 2021 Dec; 19(6):e409-e416. PubMed ID: 34116955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can immunization with Bacillus Calmette-Guérin (BCG) protect against Alzheimer's disease?
    Gofrit ON; Bercovier H; Klein BY; Cohen IR; Ben-Hur T; Greenblatt CL
    Med Hypotheses; 2019 Feb; 123():95-97. PubMed ID: 30696606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy.
    Mano R; Zilber S; Di Natale RG; Kedar D; Lifshitz DA; Yossepowitch O; Baniel J; Margel D
    Urol Oncol; 2018 Dec; 36(12):531.e9-531.e17. PubMed ID: 30337218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma].
    Kudo T; Iwasa N; Maeda S; Mitarai S
    Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical immunotherapy in nonmuscle invasive bladder cancer.
    Jokisch JF; Karl A; Stief C
    Indian J Urol; 2015; 31(4):304-11. PubMed ID: 26604441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
    Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N
    Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study.
    Hsu CW; Chiu YC; Hu HY; Fan YH; Hong SC; Cheng WM
    BMC Urol; 2020 Jul; 20(1):91. PubMed ID: 32641099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.